CIRIUM
1.12.2021 01:02:14 CET | Business Wire | Press release
The majority of Japanese travelers intend to take to the skies again, with 80% planning to travel in the next 12 months for leisure purposes (83%) and to domestic destinations, according to the new Cirium Traveler Intelligence Report.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006033/en/
Aviation analytics company Cirium records a noticeable increase in intention to travel across other markets surveyed, while travelers in Japan continue to be wary of the potential risks from COVID-19.
International travel is likely to remain difficult, however, there are encouraging indicators of recovery in Japanese domestic markets. Cirium data shows domestic traffic in Japan at 54% of 2019 levels, above the 49% average seen across APAC domestic markets excluding China.
Additionally, Cirium schedules data shows Japan is projected to reach 93% of 2019 Q1 traffic in the first quarter of 2022.
The recovery of international flights continues to be slow, but domestic traffic is recovering to pre-COVID levels experienced in 2019. According to the Cirium Japan survey, the prefectures of Sapporo and Okinawa are the most popular destinations for domestic travel, followed by Tokyo, Fukuoka and Osaka as secondary choices.
Jeremy Bowen, Cirium CEO, said: “The challenge is for airlines to make travelers feel safe about air travel and provide attractive and targeted offers to Japanese holiday makers to encourage travel.”
“At the same time, the tourism sectors needs to work collaboratively in making their region more appealing as a holiday destination and to entice Japan travelers to their prefectures.”
Further insights revealed several factors that could influence the intention to fly. One in five (20%) Japanese respondents will not book a flight until vaccines were fully deployed while almost half (42%) said a decrease in the number of COVID-19 cases will encourage travel.
Once international travel is permitted, nearly half (48%) of the respondents plan to take an international trip, with one-third selecting Europe as their choice of international destination.
The younger age group in Japan (18-29 year olds) expressed the most interest to fly again. Over two-thirds intended to fly within a year (68%) and over half (61%) plan to do so internationally with a preference for the region of East Asia.
When it comes to airline choice, Japanese carriers were clearly preferred with most citing All Nippon Airways as a favourite followed by Japan Airlines, Peach Aviation and Skymark Airlines.
Additional motivating reasons for choosing an airline over another are mandatory mask wearing on flight, requirement for health passports and improved cleaning processes on the aircraft.
The survey was carried out by independent market intelligence firm AudienceNet on behalf of Cirium. The firm interviewed over 2,092 adults in Japan between October 18 to 25, 2021. The margin of error in the reported data did not exceed +/-3% at the 95% confidence level.
Ends
Notes to editors
Click here to read the full Japan Cirium Traveler Intelligence Report.
Additional insights on air travel in the full report include:
- The importance of flying on modern aircraft
- Future use of airport lounges
- Cabin class preferences
- Top destinations in and outside of Japan
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX , a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on linkedin or visit www.cirium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130006033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom